Core Viewpoint - Hongyuan Pharmaceutical (301246.SZ) is currently trading at 21.20 yuan, reflecting a decline of 2.66% and is in a state of breaking its initial public offering price [1] Group 1: IPO Details - Hongyuan Pharmaceutical was listed on the Shenzhen Stock Exchange's ChiNext board on March 20, 2023, with an initial public offering of 47.2572 million shares at a price of 50.00 yuan per share [1] - On its first trading day, the stock reached a peak price of 45 yuan, marking the highest price since its listing [2] - The total amount raised from the IPO was 236.286 million yuan, with a net amount of 219.58437 million yuan after deducting issuance costs, exceeding the original plan by 154.51137 million yuan [2] Group 2: Fund Utilization - The company planned to use the raised funds of 65.073 million yuan for projects including a research center, multifunctional testing workshop, antiviral raw materials and intermediates project, and a high-end formulation workshop with an annual production capacity of 2.5 billion tablets (or granules) [2] - The total issuance costs for the IPO amounted to 16.70163 million yuan, with underwriting and sponsorship fees accounting for 13.93196 million yuan [2]
宏源药业跌2.66% 2023年上市即巅峰超募15亿